Biosimilars in the management of neutropenia: focus on filgrastim
Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Abstract: Advanc...
Saved in:
Main Authors: | Caselli D, Cesaro S, Aricò M |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/4d89cc2f957e45c99acdc3cadddf2ed7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Focus on biosimilar etanercept – bioequivalence and interchangeability
by: Cantini F, et al.
Published: (2018) -
Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America
by: Mendoza-Macedo,Karina, et al.
Published: (2016) -
Biosimilars and the extrapolation of indications for inflammatory conditions
by: Tesser JRP, et al.
Published: (2017) -
The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
by: Editorial Board
Published: (2021) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
by: Guariglia R, et al.
Published: (2016)